Pancreatic Cancer Research

ResearcherUniversity of Wisconsin–MadisonActive in the last 2 years

Patrick Beard Schwartz

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0002-2933-7139; OpenAlex author ID A5015462238. Sources: OpenAlex.

Their work

Papers
7 (first author 1, last author 0)
Trials
0
Grants
0
Labs led
0
Collaborators
32
Papers, trials and grants by year

2019: 2 papers · 2020: none · 2021: none · 2022: none · 2023: 2 papers · 2024: 2 papers · 2025: 1 paper

Papers 7

  1. Morbidity and Mortality Following Surgery for Pancreatic Cancer in Low- and Middle-Income Countries: A Systematic Review and Meta-Analysis. Co-author DOI 10.1002/jso.27946↗
  2. Nanodrug-bacteria conjugates-mediated oncogenic collagen depletion enhances immune checkpoint blockade therapy against pancreatic cancer. Co-author DOI 10.1016/j.medj.2024.02.012↗
  3. Aryl Hydrocarbon Receptor Knockout Accelerates PanIN Formation and Fibro-Inflammation in a Mutant Kras -Driven Pancreatic Cancer Model. First author DOI 10.1097/mpa.0000000000002357↗
  4. Racial Disparity in Pathologic Response following Neoadjuvant Chemotherapy in Resected Pancreatic Cancer: A Multi-Institutional Analysis from the Central Pancr… Co-author DOI 10.1245/s10434-022-12741-4↗
  5. The circadian clock is disrupted in pancreatic cancer. Co-author DOI 10.1371/journal.pgen.1010770↗
  6. Survival Outcomes Associated With Clinical and Pathological Response Following Neoadjuvant FOLFIRINOX or Gemcitabine/Nab-Paclitaxel Chemotherapy in Resected Pa… Co-author DOI 10.1097/sla.0000000000003468↗
  7. Editorial About: "A Prospective, Open-Label, Multicenter Phase II Trial of Neoadjuvant Therapy Using Full-Dose Gemcitabine and S-1 Concurrent with Radiation fo… Co-author DOI 10.1245/s10434-019-07737-6↗

Closest collaborators

The 25 strongest of 32 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Sean M. Ronnekleiv‐Kelly · 3 shared papers, 2023–2024 · strength 0.64
  2. kaleem sohail Ahmed · 1 shared paper, 2025 · strength 0.25
  3. Mustafa Ali Khan · 1 shared paper, 2025 · strength 0.25
  4. Syed Nabeel Zafar · 1 shared paper, 2025 · strength 0.25
  5. Morgan T. Walcheck · 1 shared paper, 2024 · strength 0.24
  6. Sharon Marie Weber · 2 shared papers, 2019 · strength 0.23
  7. David A. Kooby · 2 shared papers, 2019–2023 · strength 0.22
  8. Daniel Erik Abbott · 2 shared papers, 2019–2023 · strength 0.22
  9. Syed Ameen Ahmad · 2 shared papers, 2019–2023 · strength 0.22
  10. Hong Joo Kim · 2 shared papers, 2019–2023 · strength 0.22
  11. Nipun B. Merchant · 2 shared papers, 2019–2023 · strength 0.22
  12. Shishir Kumar Maithel · 2 shared papers, 2019–2023 · strength 0.22
  13. Zhaoting Li · 1 shared paper, 2024 · strength 0.20
  14. Yu Chen · 1 shared paper, 2024 · strength 0.20
  15. Kai Guo · 1 shared paper, 2024 · strength 0.20
  16. Quanyin Hu · 1 shared paper, 2024 · strength 0.20
  17. Shuai Ren · 1 shared paper, 2024 · strength 0.20
  18. Nataliya Volodymyrivna Uboha · 1 shared paper, 2019 · strength 0.16
  19. Gregory C. Wilson · 1 shared paper, 2023 · strength 0.15
  20. Ifeanyichukwu Chinedu Ogobuiro · 1 shared paper, 2023 · strength 0.15
  21. Alexander A. Parikh · 1 shared paper, 2023 · strength 0.15
  22. Iago De Castro Silva · 1 shared paper, 2023 · strength 0.15
  23. Rebecca Anne Snyder · 1 shared paper, 2023 · strength 0.15
  24. Chet W. Hammill · 1 shared paper, 2023 · strength 0.15
  25. Jashodeep Datta · 1 shared paper, 2023 · strength 0.15

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.